DoorDash, Inc. Class A Common Stock (DASH)vsMEDIFAST INC (MED)
DASH
DoorDash, Inc. Class A Common Stock
$156.80
-2.04%
CONSUMER CYCLICAL · Cap: $68.39B
MED
MEDIFAST INC
$12.23
-1.05%
CONSUMER CYCLICAL · Cap: $134.54M
Smart Verdict
WallStSmart Research — data-driven comparison
DoorDash, Inc. Class A Common Stock generates 4153% more annual revenue ($14.72B vs $346.10M). DASH leads profitability with a 6.3% profit margin vs -5.8%. MED appears more attractively valued with a PEG of 0.97. MED earns a higher WallStSmart Score of 45/100 (D).
DASH
Hold43
out of 100
Grade: D
MED
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+0.6%
Fair Value
$176.60
Current Price
$156.80
$19.80 discount
Intrinsic value data unavailable for MED.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 33.1% year-over-year
Large-cap with strong market position
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
6.3% margin — thin
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Weak financial health signals
ROE of -10.1% — below average capital efficiency
Revenue declined 34.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : DASH
The strongest argument for DASH centers on Revenue Growth, Market Cap. Revenue growth of 33.1% demonstrates continued momentum.
Bull Case : MED
The strongest argument for MED centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : DASH
The primary concerns for DASH are Profit Margin, Piotroski F-Score, PEG Ratio. A P/E of 74.7x leaves little room for execution misses.
Bear Case : MED
The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
DASH profiles as a hypergrowth stock while MED is a turnaround play — different risk/reward profiles.
DASH carries more volatility with a beta of 1.87 — expect wider price swings.
DASH is growing revenue faster at 33.1% — sustainability is the question.
DASH generates stronger free cash flow (420M), providing more financial flexibility.
Bottom Line
MED scores higher overall (45/100 vs 43/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DoorDash, Inc. Class A Common Stock
CONSUMER CYCLICAL · INTERNET RETAIL · USA
DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.
Visit Website →MEDIFAST INC
CONSUMER CYCLICAL · PERSONAL SERVICES · USA
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Visit Website →Compare with Other INTERNET RETAIL Stocks
Want to dig deeper into these stocks?